The role of inflammation and infection in coronary artery Disease: A clinical perspective

ACC Current Journal Review

Volumn 11, Issue 1, 2002, Pages 32-34

  McKechnie, Ronald S ^a   Rubenfire, Melvyn ^a  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; HEAT SHOCK PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY;

ARTICLE; ATHEROSCLEROTIC PLAQUE; BACTERIAL INFECTION; CELL ACTIVITY; CELL FUNCTION; CHLAMYDOPHILA PNEUMONIAE; CIGARETTE SMOKING; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HEART INFARCTION; HERPES SIMPLEX VIRUS; HUMAN; HYPERTENSION; INFLAMMATION; INFLUENZA VIRUS; LEUKOCYTE COUNT; PATHOGENESIS; RISK ASSESSMENT; RISK FACTOR; T LYMPHOCYTE; TOOTH FLORA; VIRUS INFECTION;

EID: 0036170935     PISSN: 10621458     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1062-1458(01)00531-1     Document Type: Review

References (10)

1. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839–44.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–9.
3. Ridker PM, Rifai N, Clearfield M, et al., for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959–65.
4. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: Emerging mechanistic paradigms. Circulation 1999;100:e20–8.
5. Rothwell PM, Villagra R, Gibson R, Donders RCJM, Warlow CP. Evidence of a chronic systemic cause of instability of atherosclerotic plaques. Lancet 2000;355:19–24.
6. Roivainen M, Viik-Kajander M, Palosuo T, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101:252–7.
7. Gupta S, Leatham EWQ, Carrington M, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404–7.
8. Gurfinkel E, Bozovich G, Caroca A, Beck E, Mautner B, for the ROXIS study group. Randomised trial of roxithromycin in non–Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997;350:404–7.
9. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the azithromycin in coronary artery disease: elimination of myocardial infection with chlamydia study. Circulation 1999;99:1540–7.
10. Slavkin HC, Baum BJ. Relationship of dental and oral pathology to systemic illness. JAMA 2000;284:1215–7.